Skip to main content
$9.24 $0.40 (4.5%)

02:51 PM EDT on 05/13/21

Karyopharm Therapeutics (NASDAQ:KPTI)

CAPS Rating: 3 out of 5

Current Price $9.24 Mkt Cap $663.8M
Open $8.87 P/E Ratio 0.00
Prev. Close $8.84 Div. (Yield) $0.00 (0.0%)
Daily Range $8.66 - $9.30 Volume 1,104,790
52-Wk Range $7.78 - $21.82 Avg. Daily Vol. 1,897,783

Caps

How do you think NASDAQ:KPTI will perform against the market?

Add Stock to CAPS Watchlist

All Players

32 Outperform
3 Underperform
 

All-Star Players

6 Outperform
1 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:KPTI Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

zzlangerhans (99.01)
Submitted August 16, 2015

Lots of knowledgeable commenters have been rising to the defense of Karyopharm subsequent to the stock's recent decimation. The plunge came after the company revealed a disproportionate number of cases of sepsis in the selinexor arm of the SOPRA… More

zzlangerhans (99.01)
Submitted March 26, 2015

For a while it's seemed that I've been obligated to be positive about every new biopharma I've analyzed for CAPS. Most of the time, that's been because I've only added the stock to my database after Portefeuille made me buy it for our real life… More

NASDAQ:KPTI VS S&P 500 (SPY)

NASDAQ:KPTI Summary

Fools bearish on NASDAQ:KPTI are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about KPTI.

Recs

0
Member Avatar charkowicz (< 20) Submitted: 2/21/2021 2:58:29 PM : Outperform Start Price: $14.90 NASDAQ:KPTI Score: -45.02

Institutional ownership is very high as is management's. Key partnerships with large pharma and joint projects validate products and science. Issues are whether they can expand beyond current expertise and also monetize their products.

Recs

0
Member Avatar Disciple (46.77) Submitted: 1/1/2021 9:26:09 PM : Outperform Start Price: $15.37 NASDAQ:KPTI Score: -50.22

Develops cancer fighting drugs, in a secular and needed and very lucrative industry. Currently (1/1/21), they have over a dozen drugs, in separate studies, that are steadily progressing deep through the rigorous clinical trial phases. KPTI also has R&D relationships with the Nat'l Cancer Institute.

Recs

0
Member Avatar mdriver78 (73.77) Submitted: 5/20/2020 11:24:25 AM : Outperform Start Price: $17.69 NASDAQ:KPTI Score: -83.46

Last year Karyopharm received FDA approval for a therapy called selinexor as multiple myeloma therapy in patients who have received at least four prior lines but still had refractory disease.
Multiple myeloma is a cancer of plasma cells found in the bone marrow. It’s estimated that 30,000 people are diagnosed with this form of cancer every year in the U.S. alone. There are multiple approved therapies, but it still kills about 13,000 people per year. The disease is often more managed as a chronic condition than cured, with patients hitchhiking to new drugs as old ones stop working.

Selinexor is still relatively new on the market, so its potential as a fifth-line therapy is substantial. The company estimates this market at 6,000 patients per year.

But Karyopharm is working on clinical trials designed to showcase selinexor’s ability as a second- or third-line therapy, which, at 32,000 patients per year, is a substantially larger market. Moreover, multiple myeloma patients tend to stay on their early lines of therapy for longer, meaning it’s an even larger market than just head count.

Karyopharm received data for selinexor in this group earlier this year that it believes support an additional approval with the FDA. It submitted this Supplemental New Drug Application today, meaning the company could now have access to a much larger market upon approval, something that could happen by early next year.
Moreover, Karyopharm is studying selinexor in multiple clinical trials for additional cancer types and even COVID-19! It has submitted an application for this drug in diffuse large B-cell lymphoma (DLBCL) with the FDA expected to respond by June 23, 2020.

But there are even more big catalysts in this small biotech. Karyopharm also expects Phase 3 trial results for selinexor in liposarcoma by the end of the year, and the company is expected to launch a COVID-19 trial soon.

These are big catalysts in a biotech with a market cap of just $1.3 billion. Best of all, the company has plenty of cash, reporting $385 million in cash and investments as of the end of the last quarter, which should be enough to fund it through these big near-term catalysts.

Leaderboard

Find the members with the highest scoring picks in KPTI.

Score Leader

alexeys

alexeys (94.25) Score: +187.62

The Score Leader is the player with the highest score across all their picks in KPTI.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
alexeys 94.25 6/19/2014 Underperform 1Y $41.27 -77.88% +109.74% +187.62 0 Comment
WildShaman 68.88 7/9/2018 Underperform 5Y $18.75 -51.31% +48.77% +100.07 0 Comment
BigCaps18 33.19 7/13/2020 Underperform 5Y $18.76 -51.33% +28.50% +79.83 0 Comment
Under5 68.12 2/22/2019 Outperform 5Y $4.92 +85.71% +47.56% +38.15 0 Comment
Desertdavid 94.22 6/24/2019 Outperform 1Y $6.13 +48.94% +39.80% +9.14 0 Comment
Dananator < 20 4/16/2021 Outperform 5Y $10.24 -10.84% -1.40% -9.44 0 Comment
rtmac4 < 20 3/29/2021 Outperform 5Y $9.89 -7.68% +4.04% -11.73 0 Comment
stereotyp72 78.23 4/5/2021 Outperform 5Y $10.70 -14.67% +1.97% -16.64 0 Comment
odocoileus 56.20 7/17/2019 Outperform 5Y $7.93 +15.13% +37.60% -22.47 0 Comment
charkowicz < 20 2/22/2021 Outperform 5Y $14.90 -38.72% +6.29% -45.02 1 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for KPTI.